Company intelligence / Profile preview

Delcor

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

DalCor Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of precision medicine for cardiovascular disease. The company's lead program is dalcetrapib, a small molecule CETP inhibitor being developed for patients with a specific genetic profile (ADCY9 AA genotype) who have recently experienced acute coronary syndrome. DalCor is currently conducting the Phase 3 Dal-GenE-2 trial to confirm the efficacy of dalcetrapib in reducing cardiovascular events in this genetically targeted population. By leveraging a companion diagnostic developed in collaboration with Roche, the company aims to deliver the first pharmacogenetic precision medicine in the cardiovascular space.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Roche Molecular Systems

Beyond the preview

Go deeper on Delcor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delcor.

Explore the full profile